Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
NCT ID: NCT01544894
Last Updated: 2012-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2009-09-30
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
DESIGN: Prospective, open label study. SETTING: University hospital menopause unit. PATIENTS: 80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or strontium ranelate (2g/d). Participants were followed for 1 year.
MAIN OUTCOME MEASURE(S): Compliance with each regime. Secondary objectives were parameters of efficacy, including changes in bone mineral density and bone biochemical markers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
raloxifene
60 mg/d for one year.
Raloxifene
60 mg/d for one year
strontium ranelate
2 g/d for one year.
Strontium ranelate
2 g/d, for one year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Raloxifene
60 mg/d for one year
Strontium ranelate
2 g/d, for one year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Valencia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonio Cano Sanchez
Professor in Obstetrics and Gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonio Cano, MD
Role: STUDY_DIRECTOR
University of Valencia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Dr Peset
Valencia, Valencia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sr-ral-postmOTP
Identifier Type: -
Identifier Source: org_study_id